- Stocks
- Healthcare
- NASDAQ: VRTX

Price (delayed)

$329.99

Market cap

$84.99B

P/E Ratio

25.96

Dividend/share

N/A

EPS

$12.71

Enterprise value

$76.49B

Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather

Vertex Pharmaceuticals's net income has increased by 33% YoY

The equity has grown by 32% YoY and by 3.7% from the previous quarter

The EPS has increased by 33% year-on-year but it has declined by 2% since the previous quarter

The price to earnings (P/E) is 20% less than the 5-year quarterly average of 32.4 but 12% more than the last 4 quarters average of 23.1

Vertex Pharmaceuticals's quick ratio has decreased by 11% QoQ and by 10% YoY

What are the main financial stats of VRTX

Market
Valuations
Earnings

Shares outstanding

257.55M

Market cap

$84.99B

Enterprise value

$76.49B

Price to earnings (P/E)

25.96

Price to book (P/B)

5.88

Price to sales (P/S)

9.22

EV/EBIT

18.12

EV/EBITDA

17.5

EV/Sales

8.31

Revenue

$9.21B

EBIT

$4.22B

EBITDA

$4.37B

Free cash flow

$3.89B

Per share
Balance sheet
Liquidity

EPS

$12.71

Free cash flow per share

$15.11

Book value per share

$56.14

Revenue per share

$35.77

TBVPS

$67.14

Total assets

$18.97B

Total liabilities

$4.54B

Debt

$789.2M

Equity

$14.43B

Working capital

$9.94B

Debt to equity

0.05

Current ratio

4.28

Quick ratio

3.95

Net debt/EBITDA

-1.94

Margins
Efficiency
Dividend

EBITDA margin

47.5%

Gross margin

88%

Net margin

35.4%

Operating margin

43.4%

Return on assets

18.8%

Return on equity

24.5%

Return on invested capital

95.7%

Return on capital employed

26.5%

Return on sales

45.8%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Vertex Pharmaceuticals stock price performed over time

Intraday

-0.79%

1 week

-3.43%

1 month

2.07%

1 year

22.38%

YTD

14.27%

QTD

4.74%

How have Vertex Pharmaceuticals's revenue and profit performed over time

Revenue

$9.21B

Gross profit

$8.11B

Operating income

$3.99B

Net income

$3.26B

Gross margin

88%

Net margin

35.4%

The operating income has grown by 36% year-on-year but it has declined by 6% since the previous quarter

Vertex Pharmaceuticals's net income has increased by 33% YoY

The operating margin has increased by 18% YoY but it has decreased by 9% QoQ

The gross profit has grown by 16% YoY and by 3.3% from the previous quarter

What is Vertex Pharmaceuticals's growth rate over time

What is Vertex Pharmaceuticals stock price valuation

P/E

25.96

P/B

5.88

P/S

9.22

EV/EBIT

18.12

EV/EBITDA

17.5

EV/Sales

8.31

The EPS has increased by 33% year-on-year but it has declined by 2% since the previous quarter

The price to earnings (P/E) is 20% less than the 5-year quarterly average of 32.4 but 12% more than the last 4 quarters average of 23.1

The equity has grown by 32% YoY and by 3.7% from the previous quarter

The stock's price to book (P/B) is 29% less than its 5-year quarterly average of 8.3 but 3.2% more than its last 4 quarters average of 5.7

The price to sales (P/S) is 17% less than the 5-year quarterly average of 11.1 but 7% more than the last 4 quarters average of 8.6

VRTX's revenue is up by 16% YoY and by 3.1% QoQ

How efficient is Vertex Pharmaceuticals business performance

The return on invested capital rose by 28% year-on-year but it has declined by 12% since the previous quarter

The return on sales has increased by 24% year-on-year but it has declined by 4.6% since the previous quarter

The return on equity has declined by 8% since the previous quarter

VRTX's return on assets is down by 8% since the previous quarter

What is VRTX's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for VRTX.

How did Vertex Pharmaceuticals financials performed over time

The total liabilities has increased by 36% YoY and by 7% QoQ

Vertex Pharmaceuticals's total assets has increased by 33% YoY and by 4.5% QoQ

VRTX's debt is 95% lower than its equity

The debt to equity fell by 38% YoY and by 17% QoQ

The equity has grown by 32% YoY and by 3.7% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.